Non-alcoholic fatty liver disease in 2015

World Journal of Hepatology

Volumn 7, Issue 11, 2015, Pages 1450-1459

  Ahmed, Monjur ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Fatty liver; Hepatic steatosis; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

EID: 84930854845     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i11.1450     Document Type: Review

References (75)

1. Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, Clark JM. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013; 178: 38-45 [PMID: 23703888 DOI: 10.1093/aje/kws448]
2. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307: 491-497 [PMID: 22253363 DOI:10.1001/jama.2012.39]
3. Wong VW. Nonalcoholic fatty liver disease in Asia: a story of growth. J Gastroenterol Hepatol 2013; 28: 18-23 [PMID: 23094755 DOI: 10.1111/jgh.12011]
4. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285 [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x]
5. Fan JG, Peng YD. Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies. Hepatobiliary Pancreat Dis Int 2007; 6: 572-578 [PMID: 18086620]
6. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519-1523 [PMID:21700865 DOI: 10.1126/science.1204265]
7. King MW. Introduction to Insulin Activities. 1996-2013. Available from: URL: http://themedicalbiochemistrypage.org/insulin.php
8. Garg A, Misra A. Hepatic steatosis, insulin resistance, and adipose tissue disorders. J Clin Endocrinol Metab 2002; 87: 3019-3022 [PMID: 12107193 DOI: 10.1210/jcem.87.7.8736]
9. Takaki A, Kawai D, Yamamoto K. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). Int J Mol Sci 2014; 15: 7352-7379 [PMID: 24786095 DOI: 10.3390/ ijms15057352]
10. Chalasani N, Guo X, Loomba R, Goodarzi MO, Haritunians T, Kwon S, Cui J, Taylor KD, Wilson L, Cummings OW, Chen YD, Rotter JI. Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology 2010; 139: 1567-1576, 1576.e1-6 [PMID: 20708005 DOI: 10.1053/j.gastro.2010.07.057]
11. Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Nakamura T, Teranishi H, Mizusawa S, Ueno T, Chayama K, Nakajima A, Nakao K, Sekine A, Hotta K. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet 2013; 132: 783-792 [PMID:23535911 DOI: 10.1007/s00439-013-1294-3]
12. Bhatt SP, Nigam P, Misra A, Guleria R, Pandey RM, Pasha MA. Genetic variation in the patatin-like phospholipase domaincontaining protein-3 (PNPLA-3) gene in Asian Indians with nonalcoholic fatty liver disease. Metab Syndr Relat Disord 2013; 11: 329-335 [PMID: 23734760 DOI: 10.1089/met.2012.0064]
13. Choudhury J, Sanyal AJ. Clinical aspects of fatty liver disease. Semin Liver Dis 2004; 24: 349-362 [PMID: 15605303 DOI:10.1055/s-2004-860864]
14. Armstrong MJ, Houlihan DD, Bentham L, Shaw JC, Cramb R, Olliff S, Gill PS, Neuberger JM, Lilford RJ, Newsome PN. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012; 56: 234-240 [PMID: 21703178 DOI: 10.1016/j.jhep.2011.03.020]
15. Bayard M, Holt J, Boroughs E. Nonalcoholic fatty liver disease. Am Fam Physician 2006; 73: 1961-1968 [PMID: 16770927]
16. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750 [PMID: 12198701]
17. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51: 433-445 [PMID: 19604596 DOI:10.1016/j.jhep.2009.05.023]
18. Jacobs JE, Birnbaum BA, Shapiro MA, Langlotz CP, Slosman F, Rubesin SE, Horii SC. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. AJR Am J Roentgenol 1998; 171: 659-664 [PMID: 9725292 DOI: 10.2214/ajr.171.3.9725292]
19. Mendler MH, Bouillet P, Le Sidaner A, Lavoine E, Labrousse F, Sautereau D, Pillegand B. Dual-energy CT in the diagnosis and quantification of fatty liver: limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload. J Hepatol 1998; 28: 785-794 [PMID: 9625313 DOI:10.1016/S0168-8278(98)80228-6]
20. Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy. J Magn Reson Imaging 2011; 34: spcone [PMID:22025886 DOI: 10.1002/jmri.22580]
21. Permutt Z, Le TA, Peterson MR, Seki E, Brenner DA, Sirlin C, Loomba R. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 2012; 36: 22-29 [PMID: 22554256 DOI:10.1111/j.1365-2036.2012.05121.x]
22. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16: 5286-5296 [PMID:21072891 DOI: 10.3748/wjg.v16.i42.5286]
23. Harmon RC, Tiniakos DG, Argo CK. Inflammation in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011; 5: 189-200 [PMID: 21476914 DOI: 10.1586/egh.11.21]
24. Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, Denk H. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol 2008; 48:821-828 [PMID: 18329127 DOI: 10.1016/j.jhep.2008.01.026]
25. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Heuman D, Coterrell A, Fisher RA, Contos MJ, Mills AS. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43: 682-689 [PMID: 16502396 DOI: 10.1002/hep.21103]
26. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012; 56: 1384-1391 [PMID: 22326465 DOI: 10.1016/ j.jhep.2011.10.027]
27. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:2467-2474 [PMID: 10484010 DOI: 10.1111/j.1572-0241.1999.01377.x]
28. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500 [PMID: 11172192 DOI: 10.1056/NEJM200102153440706]
29. Cichoz˙-Lach H, Celiński K, Prozorow-Król B, Swatek J, Słomka M, Lach T. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Med Sci Monit 2012; 18: CR735-CR740 [PMID:23197236 DOI: 10.12659/MSM.883601]
30. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854 [PMID: 17393509 DOI: 10.1002/hep.21496]
31. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104-1112 [PMID: 19523535 DOI: 10.1016/j.cgh.2009.05.033]
32. Borsoi Viana MS, Takei K, Collarile Yamaguti DC, Guz B, Strauss E. Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C. Ann Hepatol 2009; 8: 26-31 [PMID: 19221530]
33. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E, Sánchez-Avila F, Vargas-Vorácková F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 2008; 7:350-357 [PMID: 19034235]
34. Afdhal NH. Fibroscan (transient elastography) for the measurement of liver fibrosis. Gastroenterol Hepatol (NY) 2012; 8:605-607 [PMID: 23483859]
35. Cohen EB, Afdhal NH. Ultrasound-based hepatic elastography:origins, limitations, and applications. J Clin Gastroenterol 2010; 44: 637-645 [PMID: 20844365 DOI: 10.1097/MCG.0b013e3181e 12c39]
36. Carey E, Carey WD. Noninvasive tests for liver disease, fibrosis, and cirrhosis: Is liver biopsy obsolete?. Cleve Clin J Med 2010; 77:519-527 [PMID: 20682514 DOI: 10.3949/ccjm.77a.09138]
37. Rustogi R, Horowitz J, Harmath C, Wang Y, Chalian H, Ganger DR, Chen ZE, Bolster BD, Shah S, Miller FH. Accuracy of MR elastography and anatomic MR imaging features in the diagnosis of severe hepatic fibrosis and cirrhosis. J Magn Reson Imaging 2012; 35: 1356-1364 [PMID: 22246952]
38. Harrison SA, Day CP. Benefits of lifestyle modification in NAFLD. Gut 2007; 56: 1760-1769 [PMID: 17911352 DOI: 10.1136/ gut.2006.112094]
39. Tilg H, Moschen A. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 2010; 56: 159-167 [PMID: 20485253]
40. Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, Johnson RJ, Abdelmalek MF. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008; 48: 993-999 [PMID: 18395287 DOI: 10.1016/j.jhep.2008.02.011]
41. Simopoulos AP. Dietary omega-3 fatty acid deficiency and high fructose intake in the development of metabolic syndrome, brain metabolic abnormalities, and non-alcoholic fatty liver disease. Nutrients 2013; 5: 2901-2923 [PMID: 23896654 DOI: 10.3390/ nu5082901]
42. Al-Gayyar MM, Shams ME, Barakat EA. Fish oil improves lipid metabolism and ameliorates inflammation in patients with metabolic syndrome: impact of nonalcoholic fatty liver disease. Pharm Biol 2012; 50: 297-303 [PMID: 22103753 DOI: 10.3109/13880209.2011.604088]
43. Akyüz F, Demir K, Ozdil S, Aksoy N, Poturoğlu S, Ibrişim D, Kaymakoğlu S, Beşişik F, Boztaş G, Cakaloğlu Y, Mungan Z, Cevikbaş U, Okten A. The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. Dig Dis Sci 2007; 52: 2359-2367 [PMID: 17429734 DOI: 10.1007/s10620-006-9145-x]
44. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023 [PMID: 22488764 DOI: 10.1002/hep.25762]
45. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685 [PMID:20427778 DOI: 10.1056/NEJMoa0907929]
46. Ismail-Beigi F. Clinical practice. Glycemic management of type 2 diabetes mellitus. N Engl J Med 2012; 366: 1319-1327 [PMID:22475595 DOI: 10.1056/NEJMcp1013127]
47. Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ. The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. Therap Adv Gastroenterol 2009; 2: 157-163 [PMID: 21180541 DOI: 10.1177/1756283X09105462]
48. Mehta SR. Advances in the treatment of nonalcoholic fatty liver disease. Ther Adv Endocrinol Metab 2010; 1: 101-115 [PMID:23148155 DOI: 10.1177/2042018810379587]
49. Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, Unalp A, Tonascia J. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2009; 30: 88-96 [PMID: 18804555 DOI: 10.1016/ j.cct.2008.09.003]
50. Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, Zala JF, Helbling B, Steuerwald M, Zimmermann A. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4:1537-1543 [PMID: 17162245 DOI: 10.1016/j.cgh.2006.09.025]
51. Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rössle M, Cordes HJ, Zeuzem S, Hein J, Berg T. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52:472-479 [PMID: 20683947 DOI: 10.1002/hep.23727]
52. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39: 770-778 [PMID: 14999696 DOI: 10.1002/hep.20092]
53. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, McCullough AJ. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011; 54: 1610-1619 [PMID: 21748765 DOI: 10.1002/hep.24544]
54. Van Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM, Rinella ME. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2013; 10: 277-286 [PMID: 21677329]
55. Nseir W, Mahamid M. Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review. Curr Atheroscler Rep 2013; 15: 305 [PMID: 23328905 DOI: 10.1007/s11883-012-0305-5]
56. Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, Kakafika AI, Tziomalos K, Burroughs AK, Elisaf MS. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006; 22: 873-883 [PMID:16709309 DOI: 10.1185/030079906X104696]
57. Di Minno MN, Russolillo A, Lupoli R, Ambrosino P, Di Minno A, Tarantino G. Omega-3 fatty acids for the treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18:5839-5847 [PMID: 23139599 DOI: 10.3748/wjg.v18.i41.5839]
58. Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, Leshno M, Blendis L, Halpern Z, Oren R. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 639-644 [PMID: 16630771 DOI: 10.1016/j.cgh.2006.02.004]
59. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis:A randomized, prospective trial. Hepatology 2009; 49: 80-86 [PMID: 19053049 DOI: 10.1002/hep.22575]
60. Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006; 26: 1015-1017 [PMID:16953843 DOI: 10.1111/j.1478-3231.2006.01315.x]
61. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43: 173-181 [PMID:16374859 DOI: 10.1002/hep.21006]
62. Balaban YH, Korkusuz P, Simsek H, Gokcan H, Gedikoglu G, Pinar A, Hascelik G, Asan E, Hamaloglu E, Tatar G. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol 2007; 6:242-250 [PMID: 18007554]
63. Iwasaki T, Yoneda M, Inamori M, Shirakawa J, Higurashi T, Maeda S, Terauchi Y, Nakajima A. Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology 2011; 58: 2103-2105 [PMID: 22024083 DOI: 10.5754/hge11263]
64. Itou M, Kawaguchi T, Taniguchi E, Oriishi T, Sata M. Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report. Case Rep Gastroenterol 2012; 6: 538-544 [PMID:22949894 DOI: 10.1159/000341510]
65. Stephen S, Baranova A, Younossi ZM. Nonalcoholic fatty liver disease and bariatric surgery. Expert Rev Gastroenterol Hepatol 2012; 6: 163-171 [PMID: 22375522 DOI: 10.1586/egh.11.97]
66. Grimm IS, Schindler W, Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. Am J Gastroenterol 1992; 87: 775-779 [PMID: 1590319]
67. Morris BJ. Seven sirtuins for seven deadly diseases of aging. Free Radic Biol Med 2013; 56: 133-171 [PMID: 23104101 DOI:10.1016/j.freeradbiomed.2012.10.525]
68. Colak Y, Ozturk O, Senates E, Tuncer I, Yorulmaz E, Adali G, Doganay L, Enc FY. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit 2011; 17: HY5-HY9 [PMID: 21525818 DOI: 10.12659/MSM.881749]
69. Li L, Hai J, Li Z, Zhang Y, Peng H, Li K, Weng X. Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol 2014; 63: 166-173 [PMID: 23978414 DOI: 10.1016/j.fct.2013.08.036]
70. Mehal WZ, Iredale J, Friedman SL. Scraping fibrosis: expressway to the core of fibrosis. Nat Med 2011; 17: 552-553 [PMID:21546973 DOI: 10.1038/nm0511-552]
71. Murawaki Y, Kusakabe Y, Hirayama C. Serum lysyl oxidase activity in chronic liver disease in comparison with serum levels of prolyl hydroxylase and laminin. Hepatology 1991; 14: 1167-1173 [PMID: 1683640 DOI: 10.1002/hep.1840140635]
72. Talal AH, Feron-Rigodon M, Madere J, Subramanian GM, Bornstein JD. 1319 Simutuzumab, an antifibrotic monoclonal antibody against Lysyl Oxidase-Like 2(LOXL2) enzyme, appears safe and well tolerated in patients with liver disease of diverse etiology (Abstract). J Hepatol 2013; 58 Supplement 1: S532 [DOI:10.1016/S0168-8278(13)61319-7]
73. Gilead Sciences. Safety and Efficacy of Simtuzumab (GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: URL: http://www.clinicaltrials.gov/show/ NCT01672866 NLM Identifier: NCT01672866
74. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011; 343: d6891 [PMID:22102439 DOI: 10.1136/bmj.d6891]
75. Dela Cruz AC, Bugianesi E, George J, Day CP, Liaquat H, Charatcharoenwitthaya P, Mills PR, Dam-Larsen S, Bjornsson ES, Haflidadottir S, Adams LA, Bendtsen F, Angulo P: Characteristics and long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2014; 146: S-909 [DOI: 10.1016/ S0016-5085(14)63307-2]